Navigation Links
AMDL's Jade Pharmaceutical Subsidiary Announces New Product Strategy; Six New Products, Including One With Sales Projected at Upwards of $10 Million, Under Development
Date:9/20/2007

TUSTIN, Calif., Sept. 20 /PRNewswire-FirstCall/ -- AMDL, Inc. (Amex: ADL), headquartered in Tustin, California, with operations in Shenzhen, Jiangxi and Jilin, China, through its wholly owned subsidiary Jade Pharmaceutical Inc. (JPI), is an international biopharma company that engages in the development, manufacture and marketing of proprietary pharmaceutical and diagnostic products. AMDL announced today that JPI has a new product development strategy focusing on expanded in-house research and development activities and the in-licensing of new products from 3rd party pharmaceutical research firms.

Frank Zheng, Managing Director of JPI, stated "Our new product development strategy is expected to provide at least an additional six new products to the Company's existing family of strong selling products over the next 36 months. Additionally, JPI is regularly reviewing various other product in-licensing opportunities."

Gary Dreher, CEO of AMDL, said that "JPI's outstanding product development strategy is one of the key engines of growth for the Company."

JPI is accelerating its new product development process beyond the nine new products that have already been announced. It currently has two products under review by the SFDA (China State Food and Drug Administration), AMDL's DR-70(R) cancer diagnostic test kit and Docetaxel Injectables. Both products are anticipated to be approved for sale in China during mid-2008.

"In order for JPI to manufacture the Docetaxel Injectable product, they will be required to build a segregated product line over approximately the next 12 months," Mr. Dreher said. "Docetaxel is expected to become JPI's best selling product, with estimated sales of upwards of $10 million per year beginning in mid-2008."

Additionally, four other products are in an R&D phase, including EO-H, a herbal treatment to improve bone density, TouJin NiangShi, an herbal liver cancer treatment, and Drotaverrine Hydrochloric and Diammonium Glycyrrhizinate, which are both chemotherapy therapeutic products. All four products are currently expected to gain SFDA approval within the next 24-36 months.

Lastly, AMDL announced that all the matters voted on at the Company's annual meeting were approved by a majority of the shareholders.

About Jade: Jade has access to the fastest growing pharmaceutical and consumer market in the world: China. AMDL, through its subsidiary, Jade currently manufactures large volume injectable fluids, tablets and other related products, holding licenses for 133 products. It also manufactures 107 generic, over the counter and supplemental pharmaceutical products under certified Chinese Good Manufacturing Practice (CGMP) standards.

About AMDL: More information about AMDL and its products can be obtained at http://www.amdl.com .

Forward-Looking Statements: This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.

Contact: AMDL, Inc.

Mr. Paul Knopick

AMDL Investor Relations

Direct Line: 949.707.5365

Voice Mail: 714.505.4460


'/>"/>
SOURCE AMDL, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Analyzing Trace-Level Impurities of a Pharmaceutical Intermediate Using an LCQ Deca Ion Trap Mass Spectrometer and the Mass Frontier Software Package
2. Practical Applications of HyperDSC in a Pharmaceutical Laboratory
3. World Class Life Science and Pharmaceutical Companies Leverage DoveBid s Global Reach for Asset Management and Disposition
4. Deltanoid Pharmaceuticals begins phase II osteoporosis study
5. Doing the pharmaceutical tango
6. Want to squeeze U.S. pharmaceutical companies? Be careful what you ask for
7. The Coming of Biotech Generic Pharmaceuticals
8. Knowledge Management: The Key to Success for Life Sciences and Pharmaceutical Companies
9. Merge subsidiary to provide software to Mayo clinic
10. Merge subsidiary gets assets of Paris medical software firm
11. Renaissance Learning sells unprofitable subsidiary
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... June 27, 2016  Global demand for enzymes ... through 2020 to $7.2 billion.  This market includes ... cleaning products, biofuel production, animal feed, and other ... and biocatalysts). Food and beverages will remain the ... increasing consumption of products containing enzymes in developing ...
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , the leading software as ... Clinical Reach Virtual Patient Encounter CONSULT module which enables both audio and video ... trial team. , Using the CONSULT module, patients and physicians can schedule a face ...
(Date:6/27/2016)... , June 27, 2016   Ginkgo Bioworks ... to industrial engineering, was today awarded as one ... selection of the world,s most innovative companies. Ginkgo ... scale for the real world in the nutrition, ... engineers work directly with customers including Fortune 500 ...
(Date:6/24/2016)... ... , ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical ... mesothelioma. Their findings are the subject of a new article on the Surviving Mesothelioma ... in the blood, lung fluid or tissue of mesothelioma patients that can help point ...
Breaking Biology Technology:
(Date:5/3/2016)...  Neurotechnology, a provider of high-precision biometric identification ... Identification System (ABIS) , a complete system for ... can process multiple complex biometric transactions with high ... face or iris biometrics. It leverages the core ... MegaMatcher Accelerator , which have been used in ...
(Date:4/19/2016)... 20, 2016 The new GEZE ... compact web-based "all-in-one" system solution for all door components. ... or the door interface with integration authorization management system, ... systems. The minimal dimensions of the access control and ... building installations offer considerable freedom of design with regard ...
(Date:3/31/2016)... RATON, Florida , March 31, 2016 ... LEGX ) ("LegacyXChange" or the "Company") ... for potential users of its soon to be launched ... video ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide ... the use of DNA technology to an industry that ...
Breaking Biology News(10 mins):